Recurrent Glioblastoma Multiforme (GBM) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

Recurrent Glioblastoma Multiforme (GBM) Market Outlook

Thelansis’s “Recurrent Glioblastoma Multiforme (GBM) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Recurrent Glioblastoma Multiforme (GBM)  treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Recurrent Glioblastoma Multiforme (GBM) Overview

In adults, glioblastoma (GBM) stands as the most aggressive primary malignancy affecting the central nervous system (CNS), typically diagnosed at a median age of 65 years. Standard treatment for newly diagnosed GBM involves surgical resection to the fullest extent deemed safe, accompanied by concurrent radiotherapy and temozolomide (TMZ), followed by six-monthly cycles of adjuvant TMZ. However, options become limited when tumors progress beyond initial therapy, posing significant challenges in managing recurrent GBM (rGBM). Recurrence of GBM is virtually inevitable within a median survival period of 32–36 weeks, attributed to several factors, including the absence of a consistent definition and criteria for tumor recurrence, variations in institutional treatment approaches, and the complex, heterogeneous nature of the disease. Recurrence commonly manifests at the original tumor site in more than 90% of cases, while approximately 5% develop multiple lesions post-treatment. Additionally, GBM recurrence may occur through the emergence of new parenchymal lesions exhibiting non-continuous growth patterns, intraventricular spread, or dissemination, albeit less frequently.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Recurrent Glioblastoma Multiforme (GBM)  – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034